Bacterial peptidoglycan and immune reactivity in the central nervous system in multiple sclerosis

Ingrid A. Schrijver,1 Marjan van Meurs,1 Marie-José Melief,1 C. Wim Ang,1,2 Dragan Buljevac,2 Rivka Ravid,3 Maarten P. Hazenberg1 and Jon D. Laman1

Departments of 1Immunology and 2Neurology, Erasmus University and University Hospital Rotterdam-Dijkzigt, Rotterdam and 3Netherlands Brain Bank, Amsterdam, The Netherlands

Correspondence to: J. D. Laman, Department of Immunology, Erasmus University, Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands E-mail: laman@immu.fgg.eur.nl

Summary

Multiple sclerosis is believed to result from a CD4+ T-cell response against myelin antigens. Peptidoglycan, a major component of the Gram-positive bacterial cell wall, is a functional lipopolysaccharide analogue with potent proinflammatory properties and is conceivably a mediator of sterile inflammation. Here we demonstrate that peptidoglycan is present within antigen-presenting cells in the brain of multiple sclerosis patients. These cells have macrophage and dendritic cell characteristics, and are immunocompetent as evidenced by co-expression of inflammatory cytokines and co-stimulatory molecules. In addition, intrathecal plasma cells specific for peptidoglycan are present in multiple sclerosis brain tissue, and antibodies binding peptidoglycan are present in CSF during active disease. Peptidoglycan may thus contribute to T- and B-cell activity during brain inflammation without a requirement for local bacterial replication.

Keywords: multiple sclerosis; peptidoglycan; cytokines; antigen-presenting cells; antibodies

Abbreviations: ELISA = enzyme-linked immunosorbent assay; LPS = lipopolysaccharide; Mab = monoclonal antibody; NAMLAA = N-acetyl muramyl L-alanine amidase; PG = peptidoglycan

Introduction

According to prevailing dogma, multiple sclerosis is caused by autoreactive CD4+ T cells specific for myelin components with a proinflammatory T helper phenotype (Lassmann, 1998). Since healthy donors have similar numbers of myelin-reactive T cells to patients, additional factors are clearly needed to promote (auto)-reactivity of T cells within the CNS (Lassmann and Wekerle, 1998). Recent studies in several experimental models, including the experimental autoimmune encephalomyelitis model for multiple sclerosis, have shown that various infectious and proinflammatory agents such as lipopolysaccharide (LPS) are capable of reversing the tolerant state of CD4+ and CD8+ T cells (Röcken et al., 1992; Vella et al., 1995; Segal et al., 1997; Ehl et al., 1998). Activation of these cells is crucially dependent on the presence of both the stimulatory agent and the specific (auto)-antigen (Ehl et al., 1998). Research on inflammatory properties of bacterial antigens in brain tissue has shown that bacteria injected into the brain parenchyma are able to induce inflammatory responses only after peripheral sensitization of T cells (Matyszak, 1998). However, there is no clear evidence to date that bacterial agents or components derived thereof, such as LPS, are functionally involved in initiation or perpetuation of multiple sclerosis disease activity. In addition, studies attempting to link infectious agents to (autoimmune) inflammation are often based on the premise that replication occurs within the affected organ (Relman, 1999), but this is not necessarily the case.

Peptidoglycan (PG) is a major constituent of the cell wall of Gram-positive bacteria, which are abundantly present at all mucosa, and most prominently in the gut as part of the normal microbial flora (for review, see Hamann et al., 1998). PG is composed of long sugar chains of alternating N-acetyl glucosamine and N-acetyl muramic acid residues, which are interlinked by peptide bridges, resulting in a large complex macromolecular structure (Schleifer and Kandler, 1972). PG is only a very minor constituent of the cell wall of Gram-negative bacteria. PG can be regarded as a functional analogue of LPS, and both molecules activate innate immune defence mechanisms (Hoffmann et al., 1999). First, both molecules use CD14 on monocytes/macrophages and granulocytes as their cellular receptor, differentially engaging the recently identified Toll-like receptors (Medzhitov et al., 1997;...
Schwandner et al., 1999; Ulevitch, 1999). Secondly, the intracellular signalling pathways employed by both molecules are highly similar if not identical (Mattsson et al., 1996; Hamann et al., 1998; Gupta et al., 1999). Thirdly, both LPS and PG induce strong proinflammatory responses in vitro, including production of cytokines such as IL-1 and TNF-α (Weidemann et al., 1994; Gupta et al., 1999; Le Roy et al., 1999). LPS and PG are complex macromolecules which are difficult to digest by phagocytes (Forestier et al., 1999). Macrophages lack amidase (N-acetyl muramyl l-alanine amidase, NAMLA) expression (Hojier et al., 1996, 1997a) which is required for full degradation of PG in joint action with lysozyme (Hojier et al., 1997b). This resistance to degradation explains, at least in part, the persistence of microbial cell walls, which may be a pivotal factor in chronic (autoimmune) inflammation (Relman, 1999).

Antigen-presenting cells containing PG are present in the joints of patients with rheumatoid arthritis, possibly contributing to the local inflammatory environment (Hazenberg, 1995; Melief et al., 1995). Interestingly, PG retaining proinflammatory capacity such as the induction of TNF-α and IL-1, can be fractionated from sterile human spleen (Timmerman et al., 1993; Weidemann et al., 1994; Schrijver et al., 1999), suggesting that continuous redistribution of PG occurs from the mucosa to the secondary lymphoid organs, as well as to other anatomical sites in the absence of sepsis, and without requirement for local bacterial replication. This is fully consistent with the presence of circulating leucocytes carrying PG in human healthy subjects (Lehtonen et al., 1995) and distinct patient categories (Lehtonen et al., 1997).

In view of the strong influx of macrophages into the CNS of multiple sclerosis patients facilitated by severely impaired blood–brain barrier function (de Vries et al., 1997), we hypothesized that phagocytic antigen-presenting cells carrying PG gain access to the CNS and can locally promote immune reactivity of T and B cells. Here we show that PG-containing antigen-presenting cells are present in human multiple sclerosis brain tissue, and that they express co-stimulatory molecules and immunomodulatory cytokines. In addition, antibody forming cells specific for PG are present in human multiple sclerosis brain tissue and patients with active disease have antibodies against PG in the CSF. These findings suggest that PG affects immune reactivity in the brain.

Patients and methods

Patient samples

Human brain tissue taken at autopsy was provided by the Netherlands Brain Bank in Amsterdam (Coordinator Dr R. Ravid). Average post-mortem delay was 6 h (range 4–9 h) for multiple sclerosis patients and 8 h (range 6–10 h) for control patients. No abnormalities could be detected at autopsy in the brain tissues of the control subjects who died owing to different causes, e.g. cardiac arrest, cancer and pneumonia. Patient features are shown in Table 1.

CSF samples of 10 multiple sclerosis patients and 10 control patients were obtained from the Department of Neurology of the Erasmus University and University Hospital Rotterdam-Dijkzigt. CSF samples of relapsing–remitting multiple sclerosis patients were taken prior to immunomodulating therapy during a relapse of multiple sclerosis. Control subjects were patients who presented with severe headache for which no cause could be determined.

Immunohistochemistry

Immunohistochemical procedures used for detection of cellular subsets, antigens, antigen specific plasma cells, co-stimulatory molecules and cytokines in frozen sections have all been described in detail previously (Claassen and Jeurissen, 1998; Schrijver et al., 2000). The frozen sections were fixed in acetone with 0.5% H2O2 for 10 min. Antibodies used are shown in Table 2. To detect specific antibody forming cells, peptidoglycan–polysaccharide isolated from human faeces (Hazenberg et al., 1989) was labelled with biotin (Laman et al., 1990; Claassen et al., 1992). Sections from reactive human tonsils were included on each individual object slide to provide internal positive control tissue. Sections were evaluated by two independent observers blinded to the staining procedure.

Monoclonal antibody (Mab) against peptidoglycan (2E9)

2E9 is a murine Mab (IgG3) raised against a pure fraction of peptidoglycan–polysaccharides isolated from normal human faeces (Kool et al., 1994). The specificity of this Mab has been extensively investigated and confirmed. First, inhibition studies using enzyme-linked immunosorbent assay (ELISA) show that 2E9 recognizes cell wall fragments, muramyl dipeptide and lysozyme-solubilized cell walls of different Gram-positive bacteria (Kool et al., 1994). These experiments suggest that it binds to the glycan backbone of PG since muramic acid forms part of the structure recognized. Secondly, spleen sections of germ-free rats and of neonatal rats do. In addition, intravenous injection of PG into neonatal rats results in binding of 2E9 to phagocytes in spleen sections (Kool et al., 1994). Thirdly, immunoelectron microscopy shows that Mab 2E9 binds to cell walls of Staphylococcus epidermidis surviving intracellularly in macrophages around infected biomaterial. Fourthly, 2E9 displays no detectable reactivity against >10 000 random dodecapeptides and 8000 tripeptides in Pepscan approaches (Slootstra et al., 1997), confirming this Mab has very low crossreactivity with non-PG epitopes.

An isotype-matched control antibody (NS7, IgG3) of
<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age (years)</th>
<th>pm time (h:min)</th>
<th>Clinical and neuropathological data of multiple sclerosis cases</th>
<th>Neuropathology</th>
<th>Cause of death</th>
</tr>
</thead>
<tbody>
<tr>
<td>96–104</td>
<td>M</td>
<td>72</td>
<td>4:45</td>
<td>Disease duration: 22 years Progressive phase: 1993 1 chronic inactive lesion</td>
<td>MS with preactive plaques (MS + P)</td>
<td>Carcinoma of bladder and intestine</td>
</tr>
<tr>
<td>96–121</td>
<td>F</td>
<td>53</td>
<td>7:16</td>
<td>Disease duration: 16 years Progressive phase: 1980 Number of lesions: 4 Lesion stage: 4 active plaques</td>
<td>MS with active plaques (MS + A)</td>
<td>Pneumonia</td>
</tr>
<tr>
<td>97–006</td>
<td>F</td>
<td>62</td>
<td>6:45</td>
<td>Disease duration: 25 years Number of lesions: 2 Lesion stage: 2 active Lesions</td>
<td>MS with active plaques (MS + A)</td>
<td>Cardiac asthma</td>
</tr>
<tr>
<td>97–070</td>
<td>F</td>
<td>82</td>
<td>4:30</td>
<td>Disease duration: 15 years Progressive phase: 1975</td>
<td>MS without active lesions (MS–). Most plaques are chronic inactive, some appear remyelinated</td>
<td>Cachexia</td>
</tr>
<tr>
<td>97–077</td>
<td>M</td>
<td>50</td>
<td>5:40</td>
<td>Disease duration: 17 years ‘highly progressive MS’ Number of lesions: 3 Lesion stage: 2 chronic active, 1 chronic inactive</td>
<td>MS, the plaques are more chronic inactive than active</td>
<td>Pneumonia/ cachexia</td>
</tr>
<tr>
<td>96–040</td>
<td>F</td>
<td>35</td>
<td>5:45</td>
<td>Disease duration: 15 years ‘Very aggressive course’ Number of lesions: 5 Lesion stage: 1 active, 4 chronic active, 1 chronic inactive</td>
<td>MS with active plaques (MS + A). All plaques contain an extremely active phagocytic component</td>
<td>General decline</td>
</tr>
<tr>
<td>95–095</td>
<td>M</td>
<td>56</td>
<td>5:24</td>
<td>Disease duration: 15 years Secondary progressive</td>
<td>MS with subacute, partly chronic plaques (MS + P). Developing cerebral deterioration (senile plaques)</td>
<td>Respiratory insufficiency</td>
</tr>
<tr>
<td>96–026</td>
<td>F</td>
<td>69</td>
<td>6:40</td>
<td>Disease duration: 19 years progressive form Number of lesions: 3 Lesion stage: 3 (P) reactive</td>
<td>MS with perivascular infiltrates and leptomeningeal infiltrates (MS + P)</td>
<td>Respiratory insufficiency</td>
</tr>
<tr>
<td>96–076</td>
<td>F</td>
<td>81</td>
<td>4:15</td>
<td>Disease duration: 49 years Secondary progressive Number of lesions: 2 Lesion stage: 1 normal, 2 (P) reactive</td>
<td>MS with small plaques (MS + P). Slight senile involutive cortical changes.</td>
<td>Cachexia</td>
</tr>
<tr>
<td>96–039</td>
<td>F</td>
<td>57</td>
<td>5:45</td>
<td>Disease duration: 19 years Primary progressive Number of lesions: 5 Lesion stage: 1 active, 4 chronic inactive</td>
<td>MS with few active plaques and many subcortical plaques (MS + A)</td>
<td>Sepsis</td>
</tr>
<tr>
<td>96–074</td>
<td>F</td>
<td>40</td>
<td>7:00</td>
<td>Disease duration: 14 years Progressive phase: 1991 Number of lesions: 8 Lesion stage: 4 active, 4 chronic inactive</td>
<td>MS with extensive afflction of the white matter and many perivascular phagocytes (MS + A)</td>
<td>Dehydration</td>
</tr>
</tbody>
</table>

pm time = post-mortem delay until autopsy; MS = multiple sclerosis; MS + A = active plaques; MS + P and (P) = reactive plaques; MS– = no active plaques.
Table 2 Reagents used for the detection of various determinants

<table>
<thead>
<tr>
<th>Marker</th>
<th>Antibody clone</th>
<th>Expressed by</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD1a</td>
<td>OKT6</td>
<td>Dendritic cells, B cells</td>
</tr>
<tr>
<td>CD3</td>
<td>A452</td>
<td>Pan T cells</td>
</tr>
<tr>
<td>CD14</td>
<td>MY-4</td>
<td>Monocytes, granulocytes</td>
</tr>
<tr>
<td>CD68</td>
<td>KP-1</td>
<td>Monocytes, macrophages</td>
</tr>
<tr>
<td>CD40</td>
<td>5D12</td>
<td>Macrophages, B cells</td>
</tr>
<tr>
<td>CD80/B7.1</td>
<td>M24</td>
<td>Antigen-presenting cells</td>
</tr>
<tr>
<td>CD83</td>
<td>HB15a</td>
<td>Antigen-presenting cells</td>
</tr>
<tr>
<td>CD86/B7.2</td>
<td>1G10</td>
<td>Antigen-presenting cells</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>L243</td>
<td>Antigen-presenting cells</td>
</tr>
<tr>
<td>IL-1</td>
<td>VMP18</td>
<td>Monocytes, macrophages, dendritic cells, T/B cells, NK cells</td>
</tr>
<tr>
<td>IL-1</td>
<td>VMP20</td>
<td>Monocytes, macrophages, dendritic cells, T/B cells, NK cells</td>
</tr>
<tr>
<td>IL-4</td>
<td>Anti-IL-4 Genzyme</td>
<td>Monocytes, macrophages, dendritic cells, T/B cells, NK cells</td>
</tr>
<tr>
<td>IL-6</td>
<td>Anti-IL-6 Genzyme</td>
<td>T/B cells, macrophages</td>
</tr>
<tr>
<td>IL-10</td>
<td>B-S10</td>
<td>T cells, monocyes, macrophages</td>
</tr>
<tr>
<td>IL-12</td>
<td>Pharmingen</td>
<td>Monocytes, macrophages, B cells</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>MD-2</td>
<td>T cells, NK cells</td>
</tr>
<tr>
<td>TNF-α</td>
<td>MC16</td>
<td>Monocytes, macrophages, T cells</td>
</tr>
<tr>
<td>Peptidoglycan</td>
<td>2E9</td>
<td>Present in some antigen-presenting cells</td>
</tr>
</tbody>
</table>

irrelevant specificity (sheep red blood cells) was used throughout the studies and displayed no binding activity in brain tissue of multiple sclerosis patients or control subjects.

Statistical analysis

The number of PG-containing cells and plasma cells binding PG present in multiple sclerosis brain tissue and control brain tissue were compared using the Mann-Whitney rank-sum test. A P value < 0.05 was considered to be significant.

PG ELISA

To measure anti-PG antibodies in CSF, an ELISA, extensively validated and used before, was performed as described (Hazenberg et al., 1990). Briefly, 50 µl of peptidoglycan–polysaccharides (10 µg/ml) was coated overnight at 50°C onto 96-well polystyrene microtitre plates. Aliquots (100 µl) of 1:2, 1:4 and 1:8 dilutions of CSF were incubated during 1 h at 37°C. As detecting antibody, peroxidase conjugated rabbit anti-human IgM, IgG or IgA (Jackson Immunoresearch, Inc., Westgroove, Pa., USA) was used for 1 h at 37°C. The development of the colorimetric assay took place at 37°C for 30–45 min after the addition of 100 ml of ortho-phenylenediamine/H₂O₂. The reaction was stopped by 4 M H₂SO₄ and the optical density was measured at a wavelength of 492 nm with a Titertek Multiskan (Flow Laboratories, Irvine, Scotland). Between all incubation steps the plates were washed three times with PBS (phosphate-buffered saline)–0.02% Tween and CSF and conjugates were diluted in PBS–0.2% Tween.

Results

PG-containing cells are present in multiple sclerosis brain tissue

The presence of PG was analysed in cryo-sections of brain white matter of multiple sclerosis patients and control subjects using a monoclonal antibody against PG (Kool et al., 1994). The numbers of PG-containing cells were significantly higher in tissue from multiple sclerosis brains compared with control patients (Fig. 1) (P = 0.001). In multiple sclerosis patients, PG-containing cells were mainly present on the edge of active lesions (Lassmann et al., 1998) (Fig. 2A), as defined by Oil-red O staining for myelin breakdown products ingested by macrophages. Furthermore, PG-containing cells were present around blood vessels, or scattered in the normal appearing white matter (Fig. 2B). Only rarely could PG-containing cells be found within the fully demyelinated foci forming the centre of lesions. To further analyse the role of PG-containing cells in inflammation of the brain, double labelling was performed on brain tissue of multiple sclerosis patients selected for high numbers of PG-containing cells, to determine the phenotype and activation state of the PG-containing cells.

PG is present in macrophages and dendritic cells

To determine the phenotype of PG-containing cells, co-expression of PG with CD68, CD83, CD14, 27E10, CD1a and CD3 was analysed. Figure 3 shows that PG is mostly present in macrophages expressing CD68 and dendritic cells expressing CD83. CD14, which is the cellular receptor for both PG and LPS present on relatively immature phagocytes,
was expressed by 17% (range 0–27%) of the PG-containing cells (Weidemann et al., 1997). The majority of the PG-containing cells (mean 62%), and in two out of nine patients all of these cells (range 33–100%), expressed 27E10, an acute stage inflammatory macrophage marker characteristic for active multiple sclerosis lesions (Brück et al., 1995).

Although PG is most likely to be presented by HLA molecules, the possibility cannot be excluded that CD1a is involved in the presentation of the carbohydrate molecules present in PG. However, only very few PG-containing cells co-expressed CD1a, suggesting that this mechanism of antigen presentation is highly unlikely for PG.

**PG-containing cells co-express co-stimulatory molecules**

The capability of PG-containing cells to present antigen was examined by double staining for HLA-DR, CD80/B7–1, CD86/B7–2 and CD40, which are centrally involved in (co-)stimulation of CD4+ T cells. Co-expression with PG occurred for all four molecules to varying extents, in particular for CD80 (Fig. 2C), suggesting that PG-containing cells are mainly functionally competent, active antigen-presenting cells (Fig. 3).

**Peptidoglycan containing cells co-express different cytokines**

To assess whether PG-containing cells can contribute to CNS inflammation in multiple sclerosis by producing cytokines, double labelling was performed for proinflammatory cytokines (IL-1α and β, IL-6, IL-12, TNF-α and IFN-γ) and immunoregulatory cytokines (IL-4 and IL-10). Except for IL-1α, all cytokines analysed were expressed by PG-containing cells, to varying extents. Of the proinflammatory cytokines, co-expression was most frequently found for TNF-α (mean 44% of PG-containing cells, range 9–100%). In one patient, all PG-containing cells produced the strongly proinflammatory and myelotoxic cytokine TNF-α. In addition, TNF-α was also often strongly expressed by cells directly adjacent to PG-containing cells (Fig. 2E). Co-expression of PG was also found for IL-1β (mean 30%, range 14–52%), IL-6 (mean 11%, range 0–22%), IL-12 (mean 18%, range 0–65%) and IFN-γ (mean 11%, range 10–73%), although the latter cytokine was mostly expressed by cells directly adjacent to PG-containing cells. Immunoregulatory cytokines were prominently produced by PG-containing cells. IL-4 was detected in 58% (range 13–93%) of PG-containing cells. IL-10 was mainly produced by cells directly juxtaposed with PG-containing cells (Fig. 2D), but co-expression was found in 40% (range 0–83%) of all PG-containing cells.

**Antibody forming cells specific for peptidoglycan are present in multiple sclerosis brain tissue**

Healthy human subjects have systemic IgM, IgG and IgA levels against PG (Hazenberg et al., 1990), reflecting continuous exposure to Gram-positive bacteria at the mucosa. To determine whether intrathecal antibodies against PG were produced in multiple sclerosis brain tissue, plasma cells specific for PG were visualized in situ using biotin-labelled PG (Laman et al., 1990; Claassen et al., 1992). Plasma cells specific for PG could be detected in seven out of 13 multiple sclerosis patients and in two out of seven controls (Fig. 4). The numbers of plasma cells specific for PG were limited in control patient tissues and three of the multiple sclerosis patients; however, four multiple sclerosis patients had high numbers of PG-specific antibody forming cells. In multiple sclerosis patients, the number of antibody forming cells against PG was directly correlated with the number of PG-containing cells ($P < 0.01$). Antibody forming cells specific for PG were scattered throughout the tissue (Fig. 2F) and could often be found near blood vessels. Pre-incubation of tissue sections with unlabelled PG resulted in a dose dependent reduction of the number of PG-binding cells, confirming the specificity of staining. Double labelling for CD20, a surface plasma cell marker, IgM, IgG and PG-biotin...
confirmed that PG-binding cells were indeed plasma cells containing high levels of cytoplasmic immunoglobulin.

**Antibodies specific for peptidoglycan are present in CSF of patients with active multiple sclerosis**

To confirm our finding of intrathecal production of antibodies against PG in situ in multiple sclerosis autopsy brain tissue, ELISA was used to determine IgM, IgG and IgA antibody levels against PG in CSF samples. Samples taken during relapse from relapsing–remitting multiple sclerosis patients not treated with immunosuppressive drugs were compared with samples from patients with severe headache for which no cause could be determined. Anti-PG antibodies could not be detected in any of the control patients. Using conservative cut-off values, six out of 10 multiple sclerosis patients displayed considerable levels of anti-PG antibodies of the IgG and/or IgA isotypes (Fig. 5).
Peptidoglycan is present in macrophages and dendritic cells capable of antigen presentation. Using immunohistochemistry, double labelling was performed with the Mab 2E9 raised against peptidoglycan (PG) isolated from human faeces and various subset markers and functional markers of antigen-presenting cells. PG is present in both macrophages (CD68/27E10) and dendritic cells (CD83), which are capable of antigen presentation and co-stimulation as reflected by the expression of HLA-DR, CD40, CD80 and CD86. Horizontal bars represent mean numbers of PG-containing cells co-expressing the analysed marker.

Fig. 4 Peptidoglycan-specific plasma cells are present in multiple sclerosis brain tissue. Using biotin-labelled PG, antibody forming cells could be detected in seven of 13 multiple sclerosis patients and only in two of seven control subjects. In four of the multiple sclerosis patients (MS) relatively high numbers of antibody forming cells could be detected. Horizontal bars represent the median of the number of PG specific plasma cells in both groups.

Discussion

The current study shows that antigen-presenting cells in the CNS of multiple sclerosis patients contain the Gram-positive cell wall constituent peptidoglycan, which is abundantly present at all mucosal surfaces. In the CNS, PG may contribute to inflammation by induction of cytokine secretion, modulating T-cell function and stimulating antibody formation.

The presence of bacterial peptidoglycan in CNS tissue sheds a different light on the search for infectious agents involved in multiple sclerosis, where the emphasis has been on identification of viruses (e.g. HHV-6) and not on bacteria (Soldan et al., 1997; Noseworthy, 1999). The implicit assumption of such approaches is that local replication of viruses or bacteria is essential. In sharp contrast, we show that peptidoglycan may stimulate CNS-inflammation in the apparent local absence of viable bacteria and replication, implying that this antigen can be a microbial mediator in sterile inflammation. Thus, our data support novel emerging insights that persistence of bacterial cell wall antigens can contribute to autoimmune diseases (Relman, 1999).

Studies of autopsy brain material and multiple sclerosis routinely and consistently reveal a partial overlap of pathological characteristics between patient and control subject tissues (Ravid et al., 1995). For example, activated macrophages can be found in control subject tissues (Purba
Randolph functional maturity and loss of surface markers such as CD14 through vascular endothelium is a crucial step promoting PG in a limited number of dendritic cells.

...that antigen-presenting cells mature upon uptake of antigen and migration (Mellman et al., 1995). The high percentage of monocytes can also mature into dendritic cells, a transition enhanced by bacterial stimuli (Rescigno et al., 1997), where migration through vascular endothelium is a crucial step promoting functional maturity and loss of surface markers such as CD14 (Randolph et al., 1998). CD14+ monocytes can also mature into dendritic cells, a transition enhanced by bacterial stimuli (Rescigno et al., 1999), which may explain the presence of PG in a limited number of dendritic cells.

The expression of HLA-DR, CD40, CD80 and CD86 by PG-containing cells indicates that these cells may be potent stimulators of antigen-specific T-cell activation. In vitro analysis of PG isolated from human tissues has shown that PG is able to induce T-cell proliferation (unpublished results). In addition, PG-containing cells synthesized cytokines involved in regulation of inflammatory activity (e.g. IL-1β, IL-6, IL-12, TNF-α, IFN-γ, IL-4 and IL-10), demonstrating that they produce soluble mediators directly affecting T-cell proliferation, activation and survival (Vella et al., 1995, 1997). PG isolated from sterile human spleen is capable of inducing IL-1, IL-6 and TNF-α (Schrijver et al., 1999) by macrophages in vitro; IL-10, IFN-γ and IL-12 and gelatinase B are also induced upon PG stimulation in vitro (Schrijver et al., 2001a). This confirms that PG can indeed be responsible for the cytokine production by the PG-containing cells in the CNS.

Peptidoglycan and T-cell tolerance

We hypothesize that PG in the CNS may contribute to breaching T-cell tolerance and promotes T-cell activity by antigen presentation and induction of cytokine production (Röcken et al., 1992; Vella et al., 1995; Segal et al., 1997; Ehl et al., 1998). This is supported by the expression of HLA-DR, co-stimulatory molecules and cytokines by PG-containing cells in multiple sclerosis brain tissue. It has been shown in animal models that inflammatory processes created by bacterial infections or LPS lead to activation of autoreactive CD4+ cells (Röcken et al., 1992) or CD8+ cells (Ehl et al., 1998) which otherwise die by apoptosis. The major mechanism leading to breaking of tolerance is cytokine induction by infectious agents leading to T-cell survival (Vella et al., 1995, 1998). This view is supported by the finding that LPS induces experimental autoimmune encephalomyelitis in mice injected with myelin basic protein-specific T cells through induction of IL-12 (Segal et al., 1997). Therefore, the presence and persistence of PG in brain tissue may promote loss of tolerance against autoantigens present in the brain, e.g. myelin basic protein, proteolipid protein and others.

Intrathecal antibody synthesis against peptidoglycan

Plasma cells producing antibody specific for PG were also present in situ in multiple sclerosis brain tissue. This demonstrates that intrathecal antibody production against PG occurs. To confirm this finding, CSF of multiple sclerosis patients and control patients was analysed, showing that none of the control patients had specific antibody titres, whereas the majority of multiple sclerosis patients had detectable specific IgG and IgA levels. The presence of antibodies in the CSF may be partly due to leakage from the blood, but the presence of plasma cells specific for PG within the brain...
tissue unequivocally demonstrates that antibodies specific for PG are also produced intrathecally. The specificity and pathological relevance of plasma cells in the brain and oligoclonal immunoglobulins in multiple sclerosis has been highly obscure thus far (see Cortese et al., 1998). Our finding that PG evokes specific intrathecal antibody production in situ identifies a hitherto unknown specifity of local plasma cells.

**Perspective**

In conclusion, this study suggests that immunocompetent PG-containing cells are able to reach the brain in multiple sclerosis and may contribute to local immune reactivity, by expression of co-stimulatory molecules and cytokines, and by stimulating intrathecal antibody formation. We do not propose a single antigen–disease link. Instead we suggest that PG may be a crucial mediator in polymicrobial involvement during chronic inflammatory disease (see Kelman, 1999). Redistribution of PG from mucosal sites to the brain depends on the intricate interplay between several factors such as the permeability of the intestine, activity of enzymes specifically involved in PG degradation (Hoijer et al., 1997a) and mucosal and systemic antibody responses against PG (Schrijver et al., 2001b). Restricting the access of PG to non-mucosal sites could therefore be of clinical benefit to patients, as this may lead to lower levels of inflammation.

**Acknowledgements**

The authors wish to thank Drs R. Hintzen and D. Swaab for critical reading of this manuscript. Patient tissue samples and additional pathology information were provided by the Netherlands Brain Bank, Amsterdam, Dr B. C. Jacobs (Department of Neurology, University Hospital Rotterdam-Dijkzigt, Rotterdam) and Dr C. J. A. de Groot (Department of Pathology, Free University, Amsterdam). T. M. van Os is acknowledged for microphotography and preparing the figures. This study was in part supported by grants from NWO-NDRF (940–70–007), the EC Biomed-2 programme (BMT 97–2131), The Netherlands Foundation for the Support of Multiple Sclerosis Research (RSOE, Rotterdam Study on Exacerbations, 95–207) and the ‘Hersenstichting Nederland’ [HSN 7F99(2).49].

**References**


Bacterial peptidoglycan in multiple sclerosis 1553
I. A. Schrijver et al.


Received August 30, 2000. Revised February 20, 2001. Accepted March 20, 2001